Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3838
- Registration Number
- NCT01005056
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
Phase 3
Completed
- Conditions
- Acute Migraine With or Without Aura in Adolescents
- Interventions
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 674
- Registration Number
- NCT01004263
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1382
- Registration Number
- NCT01001234
Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 266
- Registration Number
- NCT00988260
Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1577
- Registration Number
- NCT00979901
Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1365
- Registration Number
- NCT00974571
Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1214
- Registration Number
- NCT00972738
A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 413
- Registration Number
- NCT00968149
An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Device: Multiload-cu 375®Drug: Etonogestrel-releasing IUS
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 84
- Registration Number
- NCT00967746
Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 689
- Registration Number
- NCT00968201